Catumaxomab. Anti-Ep-CAM monoclonal antibody oncolytic

Drugs of the Future

Volumn 33, Issue 5, 2008, Pages 385-391

  Revill, P ^a   Mealy, N ^a   Bozzo, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATUMAXOMAB; CISPLATIN; DEXAMETHASONE; EPITHELIAL CELL ADHESION MOLECULE; ERTUMAXOMAB; MEMBRANE ANTIGEN; PARACETAMOL; REMOVAB;

ABDOMINAL PAIN; ACCESSORY CELL; ARTICLE; ASCITES; BREAST CANCER; CARCINOMATOUS PERITONITIS; CATHETER INFECTION; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; DIZZINESS; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; EROSIVE GASTRITIS; ERYTHEMA; EXTRAVASATION; FEVER; HEADACHE; HEMORRHAGIC GASTRITIS; HUMAN; ILEUS; IMMUNOCOMPETENT CELL; INTERLEUKIN 6 BLOOD LEVEL; INTESTINE OBSTRUCTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; NAUSEA; NONHUMAN; OVARY CANCER; PERIPHERAL LYMPHOCYTE; PLEURA EMPYEMA; PNEUMONIA; PROTEIN BLOOD LEVEL; RASH; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; STOMACH CANCER; SYNCOPE; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; TUMOR CELL; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; VOMITING;

EID: 45849148541     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.05.1204087     Document Type: Article

References (53)

1. Herlyn, M., Steplewski, Z., Herlyn, D., Koprowski, H. Colorectal carcinoma-specific antigen. Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979, 76(3): 1438-42.
2. Bauerle, P.A., Gires, O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007, 96(3): 417-23.
3. Litvinov, S.V.,Velders, M.P., Bakkar, H.A., Fleuren, G.J., Warnaar, S.O. EpCAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994, 125(2): 437-46.
4. Balzar, M., Winter, M.J., de Boer, C.J., Litvinov, S.V. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999, 77(10): 699-712.
5. Went, P., Vasei, M., Bubendorf, L. et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006, 94(1): 128-35.
6. Gastl, G., Spizzo, G., Obrist, P., Dunser, M., Mikuz, G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000, 356(9246): 1981-2.
7. Spizzo, G., Went, P., Dirnhofer, S. et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006, 103(2): 483-8.
8. Went, P.T., Lugli, A., Meier, S., Gundi, M., Mirlacher, M., Sauter, G., Dirnhofer, S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35(1): 122-8.
9. Munz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., Gires, O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004, 23(34): 5748-58.
10. Osta, W.A., Chen, Y., Mikhitarian, K. et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004, 64(16): 5818-24.
11. Bohlen, H., Manzke, O., Patel, B. et al. Cytolysis of leukemic B-cells by T cells activated via two bispecific antibodies. Cancer Res 1993, 53(18): 4310-4.
12. Demanet, C., Brissinck, J., De Jonge, J., Thielemans, K. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: Increased efficacy with multiple injections and CD28-induced costimulation. Blood 1996, 87(10): 4390-8.
13. Lindhofer, H., Mocikat, R., Steipe, B., Thierfelder, S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995, 155(1): 219-25.
14. Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., Lindhofer, H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999, 163(3): 1246-52.
15. Zeidler, R., Mysliwietz, J., Csanady, M. et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000, 83(2): 261-6.
16. Riesenberg, R., Buchner, A., Pohla, H., Lindhofer, H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001, 49(7): 911-7.
17. Lindhofer, H., Menzel, H., Gunther, W., Hultner, L., Thierfelder, S. Bispecific antibodies target operationally tumor- specific antigens in two leukemia relapse models. Blood 1996, 88(12): 4651-8.
18. Ruf, P., Lindhofer, H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001, 98(8): 2526-34.
19. Ruf, P., Gires, O., Jager, M., Fellinger, K., Atz, J., Lindhofer, H. Characterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007, 97(3): 315-21.
20. Fresenius applies for marketing authorization of Removab for malignant ascites. DailyDrugNews.com 2007, December 31.
21. Schmitt, M., Schmitt, A., Reinhardt, P. et al. Opsonization with a trifunctional bispecific (αCD3 x αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004, 25(4): 841-8.
22. Schmitt, M., Gronau, S., Schmitt, A. et al. Opsonization by the bispecific trifunctional antibody removab results in an enhanced lysis of EpCAM+ squamous cell carcinoma of the upper aerodigestive tract. Blood 2002, 100(11, Part 2): Abst 3708.
23. Gronau, S.S., Schmitt, M., Thess, B. et al. Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 2005, 27(5): 376-82.
24. Sebastian, M., Jaeger, M., Kiewe, P. et al. Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3046.
25. Sebastian, M., Passlick, B., Friccius-Quecke, H. et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Cancer Immunol Immunother 2007, 56(10): 1637-44.
26. Sebastian, M., Schmittel, A., Friccius-Quecke, H. el al. Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM x anti-CD3): Results of a phase I study. Lung Cancer [11th World Conf Lung Cancer (July 3-6, Barcelona) 2005] 2005, 49(Suppl. 2): Abst P-974.
27. Passlick, B., Schmittel, A., Friccius-Quecke, H. et al. Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 2540.
28. Sebastian, M., Schuette, W., Schneller, F. et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 2548.
29. Strohlein, M.A., Lordick, F., Ruettinger, D. et al. Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial. Eur J Cancer 2005, 3(Suppl. 2): Abst 659.
30. Strohlein, M.A., Lordick, F., Ruettinger, D. et al. Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperi toneal application of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II trial. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 2529.
31. Burges, A., Wimberger, P., Kumper, C. et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 2007, 13(13): 3899-905.
32. Burges, A., Wimberger, P., Gorbounova, V. et al. Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM). Eur J Cancer 2003, 1(Suppl. 5): Abst 42.
33. Wimberger, P., Burges, A., Gorbounova, V. et al. Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study. Cancer Cell Int 2004, 4(Suppl. 1): S3.
34. Riechelmann, H., Wiesneth, M., Schauwecker, P. et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: A pilot clinical trial. Cancer Immunol Immunother 2007, 56(9): 1397-406.
35. Wiesneth, M., Reinhardt, P., Gronau, S. et al. Bispecific trifunctional MoAb-opsonised lymphocytes for anti-tumour therapy. Bone Marrow Transplant 2006, 37(Suppl. 1): Abst P402.
36. Stroehlein, M.A., Jaeger, M., Lindhofer, H., Peschel, C., Jauch, K.-W., Heiss, M.M. Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. Proc Am Soc Clin Oncol (ASCO) 2004, 23: Abst 2532.
37. Heiss, M.M., Strohlein, M.A., Jager, M. et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005, 117(3): 435-43.
38. Stroehlein, M.A., Gruetzner, U., Tarabichi, A. et al. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 2544.
39. Jaeger, M., Stroehlein, M.A., Schoberth, A., Burges, A., Heiss, M.M., Lindhofer, H. Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study. Proc Am Soc Clin Oncol (ASCO) 2004, 23: Abst 2504.
40. Wimberger, P., Schulte, A., Jager, M., Lindhofer, H., Kimmig, R., Kasimir-Bauer, S. Intraperitoneal application of the trifunctional antibody (anti-EpCAM x anti-CD3) to ovarian cancer patients with malignant ascites influences circulating tumor - and immune effector cells. Proc Amer Assoc Cancer Res (AACR) 2005, 46: Abst 4260.
41. Jaeger, M., Schoberth, A., Heiss, M.M., Lahr, A., Lindhofer, H. Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3020.
42. The efficacy and safety of the trifunctional antibody catumaxomab is documented in phase II/III study. Fresenius Biotech Press Release, June 3, 2007.
43. Parsons, S.L., Kutarska, E., Koralewski, P. et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 5520.
44. Phase II/III pivotal study with trifunctional antibody removab® shows encouraging results in malignant ascites from various cancers. Fresenius Biotech Press Release, March 22, 2007.
45. Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites. Fresenius Biotech Press Release, July 17, 2007.
46. Parsons, S., Kutarska, E., Koralewski, P. et al. Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study. Eur J Cancer Suppl [14th Eur Cancer Conf (ECCO) (Sept 23-27, Barcelona) 2007] 2007, 5(4): Abst 5001.
47. Randomized, multicenter, 2-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody Removab™ (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients (NCT00189345). ClinicalTrials.gov Web site, April 11, 2008.
48. Belau, A., Pfisterer, J., Wimberger, P. et al. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 5556.
49. Loibl, S., Pfisterer, J., Wimberger, P. et al. Randomized, multicenter, 2-dose-level, open-label, phase II a study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. Eur J Cancer Suppl [14th Eur Cancer Conf (ECCO) (Sept 23-28, Barcelona) 2007] 2007, 5(4): Abst 5005.
50. Study of the trifunctional antibody catumaxomab to treat recurrent symptomatic malignant ascites (NCT00326885). ClinicalTrials.gov Web site, April 11, 2008.
51. Safety and efficacy study of the trifunctional antibody catumaxomab to treat ovarian cancer in women after a complete response to chemotherapy (NCT00377429). ClinicalTrials.gov Web site, April 11, 2008.
52. Phase II study of the trifunctional antibody catumaxomab administered intra- and postoperatively in patients with ovarian cancer (NCT00563836). ClinicalTrials.gov Web site, April 11, 2008.
53. Phase II study with catumaxomab in patients with gastric cancer after neoadjuvant CTx and curative resection (NCT00464893). ClinicalTrials.gov Web site, April 11, 2008.